Pablo Spaletra2014-12-06Servicio de Cardiología Intervencionista y Terapias EndovascularesInstituto Cardiovascular de Buenos AiresBuenos Aires, Argentina
Pablo Spaletra2014-12-06Servicio de Cardiología Intervencionista y Terapias EndovascularesInstituto Cardiovascular de Buenos AiresBuenos Aires, Argentina
Pablo Spaletra2014-12-06Servicio de Cardiología Intervencionista y Terapias EndovascularesInstituto Cardiovascular de Buenos AiresBuenos Aires, Argentina
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....
